Keros Therapeutics Inc (KROS)

Schlusskurs vom Vortag:

$57.10

Offen:

$57.32

24-Stunden-Volumen:

436.15K

Marktkapitalisierung:

$2.23B

Einnahmen:

-

Nettoeinkommen (Verlust:

$-152.99M

KGV:

-13.19

EPS:

-4.54

Netto-Cashflow:

$-126.97M

1W Leistung:

+3.98%

1M Leistung:

-5.97%

6M Leistung:

+88.35%

1J Leistung:

+32.83%

1-Tages-Spanne:

$57.32

$62.19

52-Wochen-Spanne:

$27.02

$73.00

Keros Therapeutics Inc Stock (KROS) Company Profile

Firmenname

Keros Therapeutics Inc

Sektor

Healthcare (1223)

Branche

Biotechnology (681)

Telefon

617-314-6297

Adresse

99 Hayden Avenue, Suite 120 Building E, Lexington, MA

Mitarbeiter

26

Twitter

Nächster Verdiensttermin

2024-05-30

Neueste SEC-Einreichungen

KROS's Discussions on Twitter

Keros Therapeutics Inc Stock (KROS) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2023-12-08	Eingeleitet	Wells Fargo	Overweight
2023-07-31	Eingeleitet	Wedbush	Outperform
2023-07-26	Eingeleitet	BofA Securities	Buy
2023-02-14	Eingeleitet	Cowen	Outperform
2022-10-18	Eingeleitet	Truist	Buy
2022-07-26	Eingeleitet	BTIG Research	Buy
2020-12-08	Bestätigt	H.C. Wainwright	Buy
2020-05-04	Eingeleitet	H.C. Wainwright	Buy
2020-05-04	Eingeleitet	Jefferies	Buy
2020-05-04	Eingeleitet	Piper Sandler	Overweight
2020-05-04	Eingeleitet	SVB Leerink	Outperform

Alle ansehen

Keros Therapeutics Inc Aktie (KROS) Neueste Nachrichten

Keros Therapeutics to Present at Leerink Partners 2024 Global Biopharma Conference

GlobeNewswire Inc.

Keros Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Results

GlobeNewswire Inc.

Keros Therapeutics, Inc. (KROS) is on the Move, Here's Why the Trend Could be Sustainable

Zacks Investment Research

Does Keros Therapeutics, Inc. (KROS) Have the Potential to Rally 35.66% as Wall Street Analysts Expect?

Zacks Investment Research

Recent Price Trend in Keros Therapeutics, Inc. (KROS) is Your Friend, Here's Why

Zacks Investment Research

Wall Street Analysts Predict a 45.35% Upside in Keros Therapeutics, Inc. (KROS): Here's What You Should Know

Zacks Investment Research

Finanzdaten der Keros Therapeutics Inc-Aktie (KROS)

Keros Therapeutics Inc (KROS) Nettogewinn 2024

Keros Therapeutics Inc (KROS) Free Cashflow 2024

Keros Therapeutics Inc (KROS) Gewinn je Aktie 2024